高级搜索

改良Hyper-CVAD/MA方案治疗儿童淋巴母细胞性淋巴瘤的疗效观察

江亚军, 李秀梅, 韩秀华

江亚军, 李秀梅, 韩秀华. 改良Hyper-CVAD/MA方案治疗儿童淋巴母细胞性淋巴瘤的疗效观察[J]. 肿瘤防治研究, 2012, 39(06): 716-718. DOI: 10.3971/j.issn.1000-8578.2012.06.026
引用本文: 江亚军, 李秀梅, 韩秀华. 改良Hyper-CVAD/MA方案治疗儿童淋巴母细胞性淋巴瘤的疗效观察[J]. 肿瘤防治研究, 2012, 39(06): 716-718. DOI: 10.3971/j.issn.1000-8578.2012.06.026
Jiang Yajun, Li Xiumei, Han Xiuhua. Efficacy of Modified Hype-CVAD/MA Treatment in Children LBL[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 716-718. DOI: 10.3971/j.issn.1000-8578.2012.06.026
Citation: Jiang Yajun, Li Xiumei, Han Xiuhua. Efficacy of Modified Hype-CVAD/MA Treatment in Children LBL[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 716-718. DOI: 10.3971/j.issn.1000-8578.2012.06.026

改良Hyper-CVAD/MA方案治疗儿童淋巴母细胞性淋巴瘤的疗效观察

详细信息
    作者简介:

    江亚军(1984-),男,硕士,住院医师,主要从事血液病临床工作

    通讯作者:

    李秀梅,E-mail:jiangyajun-2001@163.com

  • 中图分类号: R733.4

Efficacy of Modified Hype-CVAD/MA Treatment in Children LBL

  • 摘要: 目的 观察改良Hyper-CVAD/MA方案在儿童淋巴母细胞性淋巴瘤(LBL)初始治疗中的临床疗效。方法总结改良Hyper-CVAD/MA方案(分为A方案和B方案)初始治疗11例儿童LBL患者的临床资料。结果11例患者共完成A方案41例次,B方案40例次,鞘内注射34例次。化疗相关不良反应主要为骨髓抑制100%(81/81)、胃肠道反应39.5%(32/81)、细菌感染33.3%(27/81)、肝损害14.8%(12/81),均未影响化疗进程。1~2疗程化疗后完全缓解(CR)27.3%(3/11 ),部分缓解(PR)45.4%(5/11),疾病稳定(SD)27.3%(3/11);3~4疗程后CR 72.7%(8/11),PR 18.2%(2/11),SD 9.1%(1/11);6~8疗程后CR 81.8%(9/11),PR 9.1%(1/11),疾病进展(PD)9.1%(1/11),总体缓解率为90.9%。中位随访时间19月,平均(23.6±15.4)月,无病生存9例,带瘤生存1例,死亡1例。结论改良Hyper-CVAD/MA方案初始治疗儿童LBL患者疗效满意,化疗相关不良反应易耐受。

     

    Abstract: Objective To study the clinical efficacy of modified Hype-CVAD/MA regimen in children lymphoblastic lymphoma (LBL) patients. Methods Eleven children LBL cases accepted modified Hype-CVAD/MA regimen were divided into group A and B. Results Eleven cases totally received 41 cycles of regimen A,40 cycles of regimen B and 34 cycles of intrathecal injection.The adverse reactions of chemotherapy included bone marrow inhibition 100% (81/81),gastrointestinal reaction 39.5% (32/81),bacterial infections 33.3% (27/81),stomatitis 30.8% (25/81),shallow phlebitis 28.3% (23/81),liver damage14.8% (12/81),but all of those didn′t affect chemotherapy process.1~2 cycles later,the complete remission (CR) rate was 27.3% (3/11),partly remission (PR) 45.4% (5/11) and disease stable (SD) 27.3% (3/11);after 3~4 cycles,CR was 72.2% (8/11),PR 18.2% (2/11) and SD 9.1% (1/11);6~8 cycles later,CR was 81.8 % (9/11),PR 9.1% (1/11),and progressive disease (PD) 9.1% (1/11).The total remission rate was 90.9%.After median 19 months (average 23.6 ± 15.4 months) follow-up,disease-free survival had 9 cases,1 case survival with tumor and 1 case death. Conclusion The efficacy of modified Hype-CVAD/MA regimen as a initial treatment in children LBL was favourable,and adverse reactions were tolerable.

     

  • [1] Sun XF,Zeng ZJ,Liu DG,et al.Modified BFM-90 regimen greatly improves treatment outcomes of Chinesechildhood and adolescent lymphoblastic lymphoma[J].Zhonghua Zhong Liu Za Zhi,2007,29(1):58-61.[孙晓非,甄子俊,刘冬耕,等.改良BFM-90方案明显改善儿童青少年淋巴母细胞型淋巴瘤的疗效[J].中华肿瘤杂志,2007,29(1):58-61.]
    [2] Shi W,Shi YK,He XH,et al.A Clinical report on modified Hyper-CVAD regimen in patients withlymphobalstic lymphoma[J].Zhonghua Yi Xue Za Zhi,2010,90(14):978-81.[施薇,石远凯,何小慧,等.改良Hyper-CVAD方案治疗前体淋巴母细胞淋巴瘤患者的临床分析 [J].中华医学杂志,2010,90(14):978-81.]
    [3] Zhang ZN,Shan YD,Li RS,et al.Union Hematology[M].Peking Union Medical College Press,2004:475.[张之南,单渊东,李蓉生,等.协和血液病学[M].北京:中国协和医科大学出版社,2004:475.]
    [4] Pan Y,Liu WP,Li JF,et al.A clinicopathological study of 96 cases of lymphoblastic lymphoma[J].Zhonghua Xue Ye Xue Za Zhi,2005,26 (4):218-22.[潘云,刘卫平,李金范,等.96例淋巴母细胞淋巴瘤临床病理分析[J].中华血液学杂志,2005,26 (4):218-22.]
    [5] Thomas DA,O′Brien S,Cortes J,et al.Outcome with the hyper-CVAD regimens in lymphoblasticlymphoma[J].Blood,2004,104(6):1624-30.
    [6] Shi W,Shi YK,He XH,et al.Efficacy of modified Hyper-CVAD regimen on non-Hodgkin′s lymphoma andsafety evaluation[J].Ai Zheng,2009,28(10):1083-7.[施薇,石远凯,何小慧,等.改良Hyper-CVAD方案治疗恶性淋巴瘤患者的安全性和疗效评价[J].癌症,2009,28(10):1083-7.]
计量
  • 文章访问数:  2761
  • HTML全文浏览量:  20
  • PDF下载量:  710
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-08-01
  • 修回日期:  2011-10-19
  • 刊出日期:  2012-06-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭